Pathogenesis of fibrosing colonopathy: The role of methacrylic acid copolymer

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 6, 1999, Pages 377-384

  Prescott, Philip ^a   Bakowski, Marie T ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Solvay Healthcare Ltd   (United Kingdom)

Author keywords

Cystic fibrosis; Fibrosing colonopathy; Methacrylic acid copolymer; Pancreatic enzymes

Indexed keywords

EXCIPIENT; KREON; METHACRYLIC ACID; NUTRIZYM 10; PANCREAS ENZYME; PANCREATIN; PANCRELIPASE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; CASE CONTROL STUDY; COLON DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG COATING; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032752908     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199910/11)8:6<377::AID-PDS448>3.0.CO;2-C     Document Type: Article

References (25)

1. Freiman, J. P. FDA report on the survey for strictures in the Cystic Fibrosis Foundation database, March 1994.
2. Smyth, R. L., van Velzen, D., Smyth, A. R., Lloyd, D. A. and Heaf, D. P. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343: 85-86.
3. Smyth, R. L., Ashby, D. and O'Hea, U. et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995; 346: 1247-1251.
4. Zerin, J. M., Kuhn-Fulton, J. and White, S. J. et al. Colonic strictures in children with cystic fibrosis. Radiology 1995; 194: 223-226.
5. Reichard, K. W., Vinocur, C. D. and Franco, M. et al. Fibrosing colonopathy in children with cystic fibrosis. J. Pediatr. Surg. 1997; 32: 237-241.
6. Jones, R., Franklin, K., Spicer, R. and Berry, J. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Letter. Lancet 1995; 346: 499.
7. van Velzen, D. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 1995; 346: 499-500.
8. Ramsden, W. H., Moya, E. F. and Littlewood, J. M. Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis. Arch. Dis. Child. 1998; 79: 339-343.
9. Knabe, N., Zak, M. and Hansen, A. et al. Extensive pathological changes of the colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343: 1230.
10. Hausler, M., Meilicke, R., Biesterfeld, S. and Heimann, G. Brief case reports. First adult patient with fibrosing colonopathy. Am. J. Gastroenterol 1998; 93: 1171-1172.
11. Ashby, D., Smyth, R. L. and Brown, P. J. Statistical issues in pharmacoepidemiological case-control studies. Stat. Med. 1998; 17: 1839-1850.
12. Bakowski, M. T. and Prescott, P. Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: implications for pathogenesis. Pharmaco-epidem. Drug Saf. 1997; 6: 347-358.
13. Solvay Healthcare. . Data on file, May 1995.
14. FitzSimmons, S. C., Burkhart, G. A. and Borowitz, D. et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N. Eng. J. Med. 1997; 336: 1283-1289.
15. Lloyd-Still, J. D., Uhing, M. R., Arango, V., Fusaro, A. and Kimura, R. E. The effect of intestinal permeability on pancreatic enzyme-induced enteropathy in the rat. J. Pediatr. Gastroenterol. Nutr. 1998; 26: 489-495.
16. Kimura, R. E., Arango, V. and Lloyd-Still, J. Indomethacin and pancreatic enzymes synergistically damage intestine of rats. Dig. Dis. Sci. 1998; 43: 2322-2332.
17. Röhm GmbH. Toxicology of Eudragit L30 D-55 and L100-55. Rohm Pharma Polymers, Darmstadt, Germany, 1993.
18. Lannon, C. L., Hinchliffe, S. A., Pope, J. D., Ball, L. M. and van Velzen, D. Ulceration of the small and large bowel mucosa in resection specimens of cystic fibrosis patients with fibrosing colonopathy. Int. J. Toxicol. 1998; 18: 77-99.
19. van Velzen, D., Ball, L. M., Dezfulian, A. R., Southgate, A. and Howard, C. V. Comparative and experimental pathology of fibrosing colonopathy. Postgrad. Med. J. 1996; 72(2): S39-S48.
20. Lannon, C. L., Ball, L. M., Miko, P., Papp, J. G. and van Velzen, D. Results of oral exposure to methacrylic acid copolymer (MACP) in a rat model of pancreatic insufficiency. Proc. XXII Int. Congr. Pediatr., Amsterdam, The Netherlands, 9-14 August 1998, p. 218., abstract no. FR-FP8-5. Van Zuiden Communications B.V., The Netherlands.
21. Lannon, C. L., Ball, L. M., Howard, C. V., Dezfulian, R. and van Velzen, D. Fibrosing colonopathy after exposure to methacrylic acid copolymer (MACP) in the chronically caecal gavage pig model. Proc. XXII. Int. Congr. Pediatr., Amsterdam, The Netherlands, 9-14 August 1998, p. 247., abstract no. P072. Van Zuiden Communications B.V., The Netherlands.
22. Kastner, W. Pharmacological properties. In: Anionic Surfactants. Gloxhuber, C. and Kunstler, K. (Eds), Marcel Dekker Inc, New York, 1992, pp. 419-445.
23. Frondoza, C. G., Tanner, K. T., Jones, L. C. and Hungerford, D. S. Polymethylmethacrylate particles enhance DNA and protein synthesis of human fibroblasts in vitro. J. Biomed. Mater. Res. 1993; 27:611-617.
24. American Academy of Paediatrics Committee on Drugs. 'Inactive' ingredients in pharmaceutical products: update (subject review). Paediatrics 1997; 99: 268-278.
25. The Safety Committee of the International Pharmaceutical Excipients Council. A new approach to the safety assessment of pharmaceutical excipients. Regulat. Taxicol. Pharmacol. 1996; 24: 149-154.